| Primary |
| Aspergillosis |
14.5% |
| Systemic Candida |
13.8% |
| Pyrexia |
12.6% |
| Prophylaxis |
7.8% |
| Graft Versus Host Disease |
6.7% |
| Diabetes Mellitus |
5.2% |
| Sepsis |
4.1% |
| Hypertension |
3.7% |
| Pulmonary Oedema |
3.7% |
| Bacterial Infection |
3.3% |
| Candidiasis |
3.3% |
| Immunosuppression |
3.0% |
| Infection Prophylaxis |
3.0% |
| Pneumonia |
2.6% |
| Antibiotic Prophylaxis |
2.2% |
| Bronchopulmonary Aspergillosis |
2.2% |
| Infection |
2.2% |
| Prophylaxis Against Graft Versus Host Disease |
2.2% |
| Conjunctivitis |
1.9% |
| Gastritis |
1.9% |
|
| Septic Shock |
11.6% |
| Respiratory Failure |
8.7% |
| Venoocclusive Liver Disease |
8.7% |
| Bradycardia |
7.2% |
| Death |
7.2% |
| Fungal Infection |
5.8% |
| Metabolic Acidosis |
5.8% |
| Pulmonary Embolism |
5.8% |
| Ventricular Fibrillation |
5.8% |
| Multi-organ Failure |
4.3% |
| Bronchospasm |
2.9% |
| Drug Ineffective |
2.9% |
| Duodenal Ulcer Haemorrhage |
2.9% |
| Haemodynamic Instability |
2.9% |
| Infusion Related Reaction |
2.9% |
| Nephritic Syndrome |
2.9% |
| Pneumonia Bacterial |
2.9% |
| Renal Failure |
2.9% |
| Renal Failure Acute |
2.9% |
| Rhabdomyolysis |
2.9% |
|
| Secondary |
| Systemic Candida |
18.0% |
| Aspergillosis |
12.5% |
| Prophylaxis |
7.8% |
| Product Used For Unknown Indication |
7.1% |
| Bronchopulmonary Aspergillosis |
5.4% |
| Acute Myeloid Leukaemia |
5.1% |
| Antibiotic Therapy |
4.7% |
| Candidiasis |
4.7% |
| Fungal Infection |
4.4% |
| Graft Versus Host Disease |
4.1% |
| Lymphoma |
4.1% |
| Pulmonary Oedema |
3.4% |
| Aspergillus Infection |
3.1% |
| Pyrexia |
3.1% |
| Candida Sepsis |
2.7% |
| Antibiotic Prophylaxis |
2.4% |
| Chemotherapy |
2.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Conjunctivitis |
1.7% |
| Diabetes Mellitus |
1.7% |
|
| Respiratory Failure |
19.8% |
| Renal Failure Acute |
9.9% |
| Septic Shock |
8.6% |
| Death |
7.4% |
| Venoocclusive Liver Disease |
7.4% |
| Klebsiella Bacteraemia |
4.9% |
| Liver Function Test Abnormal |
4.9% |
| Hepatic Failure |
3.7% |
| Hyperkalaemia |
3.7% |
| Pneumonitis |
3.7% |
| Pulmonary Embolism |
3.7% |
| Acute Hepatic Failure |
2.5% |
| Ileus Paralytic |
2.5% |
| Infusion Related Reaction |
2.5% |
| Liver Injury |
2.5% |
| Multi-organ Failure |
2.5% |
| Neurotoxicity |
2.5% |
| Pneumonia Bacterial |
2.5% |
| Sepsis |
2.5% |
| Tachypnoea |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
56.9% |
| Drug Use For Unknown Indication |
10.4% |
| Acute Myeloid Leukaemia |
6.2% |
| Candidiasis |
2.9% |
| Klebsiella Infection |
2.9% |
| Escherichia Infection |
2.6% |
| Peritonitis |
2.6% |
| Prophylaxis |
2.2% |
| Bone Marrow Conditioning Regimen |
1.6% |
| Acute Lymphocytic Leukaemia |
1.4% |
| Chronic Myeloid Leukaemia |
1.4% |
| Hypertension |
1.3% |
| Septic Shock |
1.1% |
| Bronchopulmonary Aspergillosis |
1.0% |
| Endocarditis Staphylococcal |
1.0% |
| Non-hodgkin's Lymphoma |
1.0% |
| Sepsis |
1.0% |
| Small Intestinal Obstruction |
1.0% |
| Trichosporon Infection |
1.0% |
| Analgesic Therapy |
0.8% |
|
| White Blood Cell Count Decreased |
9.6% |
| Hypoxia |
7.7% |
| International Normalised Ratio Increased |
7.7% |
| Thrombocytopenia |
7.7% |
| Fungaemia |
5.8% |
| Sepsis |
5.8% |
| Toxic Epidermal Necrolysis |
5.8% |
| Asthenia |
3.8% |
| Cardiac Failure |
3.8% |
| Death |
3.8% |
| Drug Interaction |
3.8% |
| General Physical Health Deterioration |
3.8% |
| Haemoptysis |
3.8% |
| Hypotension |
3.8% |
| Multi-organ Failure |
3.8% |
| Respiratory Failure |
3.8% |
| Serotonin Syndrome |
3.8% |
| Vaginal Candidiasis |
3.8% |
| Vaginal Cellulitis |
3.8% |
| Venoocclusive Disease |
3.8% |
|
